Literature DB >> 18158784

Preparation and characterization of agonistic monoclonal antibodies against Toll-like receptor 4-MD-2 complex.

Uleng Bahrun1, Masao Kimoto, Hiroki Tsukamoto, Naoko Tsuneyoshi, Jun Kohara, Kenji Fukudome.   

Abstract

Ligands for toll-like receptors (TLR) are known to induce a variety of immune responses. Selective induction of desirable responses would be important for the treatment of individual diseases with various pathogenesis. For this purpose, we established six MAbs against the TLR4/MD-2 complex (UT MAbs) from TLR4(-/-) mice or MD-2(-/-) mice. Three MAbs (UT12, 18, and 22) induced NF-kappaB activation and production of pro-inflammatory cytokines, but the other three (UT15, 41, and 49) did not induce such cell responses. Unlike lipopolysaccharide (LPS), agonistic UT MAbs did not require serum components for the functions. UT41 and UT49 recognized TLR4 in the absence of MD-2. On the other hand, the other four MAbs reacted to the TLR4/MD-2 complex, but not to solo TLR4. Agonistic UT MAbs shared the epitopes, but non-agonistic UT15 reacted to distinct epitope on the complex. UT MAbs appear to be useful analyzing the molecular mechanism of TLR signaling and will contribute to the development of novel immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158784     DOI: 10.1089/hyb.2007.0523

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  7 in total

1.  CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance.

Authors:  Rajesh Rajaiah; Darren J Perkins; Derek D C Ireland; Stefanie N Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-23       Impact factor: 11.205

2.  An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.

Authors:  Hiroki Tsukamoto; Kanae Kubota; Ayumi Shichiku; Masamitsu Maekawa; Nariyasu Mano; Hideo Yagita; Shoichiro Ohta; Yoshihisa Tomioka
Journal:  Immunology       Date:  2019-10       Impact factor: 7.397

3.  Lipopolysaccharide (LPS)-binding protein stimulates CD14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1-IKKϵ-IRF3 axis activation.

Authors:  Hiroki Tsukamoto; Shino Takeuchi; Kanae Kubota; Yohei Kobayashi; Sao Kozakai; Ippo Ukai; Ayumi Shichiku; Misaki Okubo; Muneo Numasaki; Yoshitomi Kanemitsu; Yotaro Matsumoto; Tomonori Nochi; Kouichi Watanabe; Hisashi Aso; Yoshihisa Tomioka
Journal:  J Biol Chem       Date:  2018-05-14       Impact factor: 5.157

4.  Endosomal Sequestration of TLR4 Antibody Induces Myeloid-Derived Suppressor Cells and Reverses Acute Type 1 Diabetes.

Authors:  Kathryn C S Locker; Kritika Kachapati; Yuehong Wu; Kyle J Bednar; David Adams; Caroline Patel; Hiroki Tsukamoto; Luke S Heuer; Bruce J Aronow; Andrew B Herr; William M Ridgway
Journal:  Diabetes       Date:  2022-03-01       Impact factor: 9.461

5.  Reversal of New-Onset Type 1 Diabetes With an Agonistic TLR4/MD-2 Monoclonal Antibody.

Authors:  Kyle J Bednar; Hiroki Tsukamoto; Kritika Kachapati; Shoichiro Ohta; Yuehong Wu; Jonathan D Katz; Dana P Ascherman; William M Ridgway
Journal:  Diabetes       Date:  2015-06-30       Impact factor: 9.337

Review 6.  Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes.

Authors:  Arata Itoh; William M Ridgway
Journal:  Immunotargets Ther       Date:  2017-05-19

7.  A mouse model of human TLR4 D299G/T399I SNPs reveals mechanisms of altered LPS and pathogen responses.

Authors:  Katharina Richard; Kurt H Piepenbrink; Kari Ann Shirey; Archana Gopalakrishnan; Shreeram Nallar; Daniel J Prantner; Darren J Perkins; Wendy Lai; Alexandra Vlk; Vladimir Y Toshchakov; Chiguang Feng; Rachel Fanaroff; Andrei E Medvedev; Jorge C G Blanco; Stefanie N Vogel
Journal:  J Exp Med       Date:  2021-02-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.